In this study, we evaluated the Sofia Streptococcus pneumoniae FIA test (Quidel Corporation, San Diego, CA, USA), a new immunofluorescence-based lateral flow test for the qualitative detection of S. pneumoniae antigen in urine or cerebrospinal fluid specimens. The analyses of 100 non-concentrated urine samples (including 50 samples from S. pneumoniae cases) showed a sensitivity and specificity (95 % CI) of, respectively, 66.0 % (52.2-77.6) and 100.0 % (92.9-100.0) for the Sofia test, and 62.0 % (48.2-74.1) and 98.0 % (89.5-99.7) for the BinaxNOW SPN Antigen Card. There were no significant differences in sensitivity and specificity between the tests (McNemar's tests, P=0.625 and P=1.000). In conclusion, this study indicates that the Streptococcus pneumoniae FIA test shows similar sensitivity and specificity rates compared to the BinaxNOW SPN Antigen Card.
INTRODUCTION
Streptococcus pneumoniae is the most common cause of community-acquired pneumonia (CAP) in adults, which is the leading infection-related cause of death in developed countries [1] . Furthermore, S. pneumoniae is responsible for other serious invasive pneumococcal diseases such as bacteraemia and meningitis [2] .
Laboratory diagnosis is typically established by observation of S. pneumoniae in a Gram-stained sputum sample, or growth of S. pneumoniae in a culture of specimens such as blood, cerebrospinal fluid, sputum or other respiratory samples. However, the conventional culture-based methods are known to be relatively low (<30 % for blood culture and 57 % for sputum culture) [3] and are relatively slow (>24 h).
Several studies have indicated that patients who receive early antibiotic treatment have a lower mortality [4, 5] . This implies that next-generation urinary antigen tests, as compared to culture and conventional urinary antigen tests, are of increasing clinical importance due to their increased sensitivity, their value in patients with negative cultures due to prior antibiotic use [6] , and rapid turnaround time (TAT) ( 10 min). The aim of this study was to evaluate the Sofia Streptococcus pneumoniae FIA test (Quidel Corporation, San Diego, CA, USA), a new immunofluorescence-based lateral flow test for the qualitative detection of S. pneumoniae antigen in urine specimens.
METHODS

Sample selection
The Sofia test was evaluated using a panel of 100 nonconcentrated frozen (À70 C) urine samples. Of these samples, 50 (collected between 2014 and 2017) were derived from S. pneumoniae cases and 50 (collected between 2003 and 2017) from patients with suspected respiratory tract infection who did not test positive for S. pneumoniae.
The 50 S. pneumoniae cases were defined as patients with a suspected lower respiratory tract infection who tested positive for S. pneumoniae in one or more of the following diagnostic tests: bacteria cultured from blood, or bacteria cultured from sputum. Positive laboratory tests in the 50 S. pneumoniae cases were: urine antigen and sputum culture, 3/50 (6.0 %); urine antigen and blood culture, 23/50 (46.0 %); urine antigen, sputum culture and blood culture, 2/50 (4.0 %); sputum culture only, 8/50 (16 %); blood culture only, 11/50 (22.0 %); and sputum culture and blood culture, 3/50 (6.0 %)
The 50 non-S. pneumoniae cases were defined as patients with a suspected respiratory tract infection caused by pathogens other than S. pneumoniae. The laboratory test results for these patients were as follows: Legionella pneumophila [total, 18 patients: Legionella antigen (BinaxNOW, Alere, Waltham, ME) detected in urine; and bacteria cultured from sputum (sputum), 18 patients]; Staphylococcus aureus [total, 6 patients: sputum, 4 patients; bacteria cultured from blood (blood), 2 patients]; Moraxella catarrhalis (sputum, 1 patient); Haemophilus influenzae (sputum, 12 patients); Escherichia coli (total, 4 patients: sputum, 3 patients; blood, 1 patient); Enterobacter cloacae (blood, 1 patient); Pseudomonas aeruginosa (total, 2 patients: sputum, 2 patients; blood, 1 patient); Proteus mirabilis (blood, 1 patient); Acinetobacter baumannii (sputum, 1 patient); and Klebsiella pneumoniae (total, 3 patients: sputum, 1 patient; blood, 2 patients). Of these 50 patients, four showed positive test results for more than one pathogen: P. aeruginosa (sputum) and S. aureus (sputum), 1 patient; P. aeruginosa (sputum) and K. pneumoniae (sputum), 1 patient; K. pneumoniae (blood) and E. coli (blood), 1 patient; K. pneumoniae (blood) and E. coli (sputum), 1 patient.
Urinary antigen tests
The Streptococcus pneumoniae FIA test (Quidel Corporation, San Diego, CA) is a new immunofluorescence-based lateral flow test for the detection of S. pneumoniae antigen in urine or cerebrospinal fluid (CSF) specimens. In short, a swab is dipped in the urine or CSF sample and placed into the Sofia analyser. After 10 min, test results are available from the analyser which produces a quantitative, objective test result. In this study only urine samples were investigated.
The BinaxNOW SPN Antigen Card (Alere Inc., Waltham, MA) is an in vitro immunochromatographic test used widely for the detection of S. pneumoniae antigen in urine. In short, a swab is dipped in the urine sample, inserted into the test card and reagent buffer is added. After 15 min of incubation, test results can be manually read and interpreted by the presence or absence of a pink/purple-coloured line.
Study procedure
The results of the Sofia testing of urine samples from S. pneumoniae cases were analysed to assess its diagnostic sensitivity, and this was compared to the diagnostic sensitivity of the BinaxNOW test. The 50 urine samples from the non-S. pneumoniae cases were used to assess the diagnostic specificity of both tests.
Both tests were performed simultaneously on the defrosted urine samples, according to the manufacturer's instructions.
Non-concentrated urine samples showing discordant results between the two tests were heated in a VWR analogue heat block at 95 C for 5 min and then re-tested. For all non-concentrated urine samples from S. pneumoniae cases for which either one or both of the tests yielded a negative result, the urine was concentrated using a static ultrafiltration concentrator with a nominal molecular weight limit of 15 kDa (Minicon B15, Merck Millipore Ltd, Billerica, MA) and re-tested.
Statistical analyses
The diagnostic sensitivity and specificity of both tests were determined using two-by-two contingency tables. Diagnostic sensitivity was defined as the proportion of S. pneumoniae cases correctly identified by each of the tests, while diagnostic specificity was defined as the proportion of non-S. pneumoniae cases correctly identified by both. McNemar's test was used to compare sensitivity and specificity between the two tests. All analyses were performed in IBM SPSS Statistics 22.0.
RESULTS
Analyses of the 100 non-concentrated urine samples showed a sensitivity and specificity (95 % CI) of, respectively, 66.0 % (52.2-77.6) and 100.0 % (92.9-100.0) for the Sofia test, and 62.0 % (48.2-74.1) and 98.0 % (89.5-99.7) for the BinaxNOW. There were no significant differences in sensitivity and specificity between the tests (McNemar's test, P=0.625 and P=1.000) ( Table 1) .
Regarding the five non-concentrated urine samples, the Sofia test and BinaxNOW showed discordant results: one sample from a non-S. pneumoniae case and four samples from a S. pneumoniae case. One sample from a S. pneumoniae case yielded a negative Sofia result and a positive BinaxNOW result; three samples from S. pneumoniae cases showed a positive Sofia result and a negative BinaxNOW result; and one sample from a non-S. pneumoniae patient yielded a negative Sofia result and a positive BinaxNOW result. All five samples were heated at 95 C for 5 min and re-tested again with both methods, but this did not change the results. The four discordant samples derived from S. pneumoniae cases were concentrated and re-tested using both methods. The sample negative for Sofia and positive for BinaxNOW showed positive results for both tests after concentration. One of the samples positive for Sofia and negative for BinaxNOW yielded positive results for both tests after concentration. The other two samples, positive for Sofia and negative for BinaxNOW, yieldeded the same results after concentration.
In total, 16 urine samples from S. pneumoniae cases showed negative results for both tests.
After concentration of these samples, one sample was positive for both methods; three samples were positive for Sofia and negative for BinaxNOW; and one was negative for Sofia and positive for BinaxNOW. The remaining 11 samples remained negative for both methods.
These additional analyses showed a sensitivity and specificity (95 % CI) of, respectively, 76 % (62.6-85.7) and 100.0 % (92.9-100.0) for the Sofia test, and 68.0 % (54.2-79.2) and 98.0 % (89.5-99.7) for BinaxNOW after the heating and concentration procedures as described (no significant differences in sensitivity and specificity between both tests: McNemar's test, P=0.219 and P=1.000) ( Table 1) .
DISCUSSION
This study showed a comparable performance for the Sofia Streptococcus pneumoniae FIA test (Quidel Corporation, San Diego, CA) and the BinaxNOW SPN Antigen Card (Alere Inc., Waltham, MA) in the detection of S. pneumoniae antigen in urine samples, with respect to both sensitivity (Sofia test: 66.0 % vs. BinaxNOW test 62.0 %, P=0.625) and specificity (Sofia test 100.0 % vs. BinaxNOW test 98.0 %, P=1.00).
The study of Vicente et al. [7] reported a sensitivity for the Sofia test of 77.4 % based on a sample of 31 patients with confirmed pneumococcal pneumonia. The difference in reported sensitivity of the Sofia test compared to our results may have been caused by the selection of urine samples from the S. pneumoniae cases in both studies. Vicente et al. [7] selected urine samples from 31 pneumococcal pneumoniae cases diagnosed by blood culture (n=5) and/or sputum culture (n=19) and/or (BinaxNOW) antigen detection (n=19). In our study, there were no samples from S. pneumoniae cases included based on (BinaxNOW) antigen testing alone: all cases showed S. pneumoniae-positive blood culture and/or sputum culture was available. As reported by Vicente et al [7] , most false-negative results according to the Sofia test were in relation to urine samples corresponding with S. pneumoniae pneumonia confirmed only by sputum or blood culture: the BinaxNOW antigen test was also negative for all of these samples. This may have resulted in the higher proportion of false-negative results found in our study sample, as it is well known that S. pneumoniae antigen is not always detected in blood or sputum culture-positive patients [8] .
Several other studies have demonstrated that BinaxNOW has a sensitivity of 77-92 %, [9] [10] [11] [12] [13] in the diagnosis of bacteraemic pneumococcal pneumonia, and 52-78 % in the diagnosis of non-bacteraemic pneumococcal pneumonia [9] [10] [11] 14] , suggesting that the urinary antigen test is more sensitive in bacteraemic patients [13] . This may possibly explain the lower sensitivity of the BinaxNOW of 62 % compared to some previous studies, as 7 of the 11 urine samples from S. pneumoniae cases diagnosed by sputum culture (with no positive blood culture) tested false-negative by BinaxNOW.
Although both the Sofia test and BinaxNOW showed relatively high specificity, there was one urine sample that was classified as a false-positive by the latter test. This sample was derived from a legionellosis case as evidenced by a Legionella pneumophila serogroup 1 isolate isolated from a sputum sample. Heat treatment of this sample did not change this result. Furthermore, there was no evidence of a double infection with Legionella and S. pneumoniae. Vicente et al. suggested prior heating of urine samples to increase the specificity of the Sofia test, as was shown in their study [7] . Our data do not support these findings, as no false-positive samples were found in the Sofia test results and the false-positive BinaxNOW result did not change after heating.
After concentrating the discordant samples from the S. pneumoniae cases and re-analysing them, the sensitivity of both methods increased as five and three additional urine samples were positive by the Sofia test and BinaxNOW, respectively, after concentration. This may indicate that a concentration step would increase sensitivity in both tests, although we have not established the potential impact of concentration on the number of false-positive samples because urine samples from non-S. pneumoniae cases were neither concentrated nor re-tested in this study.
One of the limitations of this study was the lack of clinical data on patients from whom the urine samples were derived. Unfortunately, no data were available on severity of disease, antibiotic treatment and other aspects that could have been helpful in understanding some of our results. In addition, the inclusion of more sensitive reference test results, such as PCR, in the case definition of S. pneumoniae cases may help with regard to including specimens from patients with clinical symptoms in keeping with pneumococcal infection and in whom no pathogen was isolated or detected by other tests.
Furthermore, several studies have suggested that severity of disease and timing of diagnostic testing may influence the performance of S. pneumoniae antigen tests [13] .
In conclusion, this study indicates that the Streptococcus pneumoniae FIA test shows similar sensitivity and specificity rates compared to the BinaxNOW SPN Antigen Card.
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